Nivolumab,Relatlimab
bms
['2mo', 'sclc', 'relatlimab', 'nivolumab', 'impact,(-impacte),(-impacti),(-impactf)', 'nsclc', 'increase,(-increased)', 'able,(-kable),(-eable)', 'nivo', 'melanoma', 'imab ']
lag3 was discovered ! anti-lag3 will impact nsclc survival as in melanoma? no clear signal so far: in 2x30 patients with resectable nsclc, relatlimab combined with nivolumab did not increase pathological response compared to nivo alone. similar 12mo dfs. #esmo22 
Medical Oncologist - Lung cancer & thymic tumors. Head of Clinical Research @GustaveRoussy - Head of Scientific Chairs Council @EORTC. Tweets are my own.